Welcome to our dedicated page for Neogenomics news (Ticker: NEO), a resource for investors and traders seeking the latest updates and insights on Neogenomics stock.
NeoGenomics, Inc. reports developments in oncology diagnostic testing, cancer genetics and information services. The company serves oncologists, pathologists, hospital systems, academic centers and pharmaceutical firms through cancer-focused laboratory testing, professional interpretation, clinical trial and research services, validation laboratory services and oncology data solutions.
Recurring news themes include clinical revenue trends, next-generation sequencing growth, reimbursement and coverage decisions, and additions to the company’s testing menu. Updates also cover products such as PanTracer LBx, PanTracer Tissue and RaDaR ST, electronic health record access through Epic Aura, research presentations using Oncology Data Solutions, and the operation of CAP-accredited and CLIA-certified laboratory capabilities in the United States and the United Kingdom.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
NeoGenomics, Inc. (NASDAQ:NEO) announced that it will release its first quarter 2023 financial results on May 8, 2023, followed by a webcast and conference call at 4:30 p.m. Eastern Time. Interested investors can join the call via telephone or access it through the company's Investor Relations website. The company specializes in cancer genetics testing and offers a wide range of oncology-focused testing services. NeoGenomics operates CAP accredited and CLIA certified laboratories across the United States and internationally, serving a diverse clientele in the oncology field. This upcoming financial announcement is crucial for investors tracking the company's performance and strategic initiatives.
NeoGenomics, Inc. (NASDAQ: NEO), a prominent provider of cancer-focused genetic testing and oncology contract research services, will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, at 11:00am ET. A live audio webcast will be accessible via the Investor Relations section of their website.
NeoGenomics specializes in cancer genetics testing, offering a wide range of testing options to assist healthcare providers in diagnosing and treating cancer. The company also supports pharmaceutical clients through clinical trials and drug development.
Headquartered in Fort Myers, Florida, NeoGenomics operates accredited laboratories across the U.S. and internationally. They are dedicated to connecting patients with transformative therapies while ensuring compliance with data protection laws.